See more : Creative Media & Community Trust Corporation (CMCTP) Income Statement Analysis – Financial Results
Complete financial analysis of Precipio, Inc. (PRPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precipio, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Vivoryon Therapeutics N.V. (0R3M.L) Income Statement Analysis – Financial Results
- NANSO Transport Co.,Ltd. (9034.T) Income Statement Analysis – Financial Results
- Kirloskar Brothers Limited (KIRLOSBROS.NS) Income Statement Analysis – Financial Results
- Lion Corporation (LIOPF) Income Statement Analysis – Financial Results
- IOG plc (IOG.L) Income Statement Analysis – Financial Results
Precipio, Inc. (PRPO)
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.20M | 9.41M | 8.85M | 6.09M | 3.13M | 2.86M | 1.72M | 1.56M | 1.65M | 27.08M | 27.54M | 31.48M | 31.97M | 20.05M | 22.02M | 23.99M | 23.18M | 23.42M | 25.83M | 33.79M | 33.87M | 37.55M | 38.47M | 25.88M | 23.03M |
| Cost of Revenue | 9.18M | 6.90M | 6.46M | 4.94M | 2.91M | 2.64M | 1.43M | 1.76M | 1.94M | 17.36M | 15.05M | 16.47M | 13.53M | 10.28M | 10.42M | 10.35M | 10.48M | 12.05M | 13.50M | 24.60M | 24.32M | 19.57M | 17.20M | 10.89M | 10.58M |
| Gross Profit | 6.02M | 2.51M | 2.39M | 1.15M | 219.00K | 225.00K | 292.00K | -205.00K | -287.00K | 9.72M | 12.50M | 15.01M | 18.44M | 9.76M | 11.61M | 13.65M | 12.69M | 11.37M | 12.33M | 9.19M | 9.55M | 17.99M | 21.27M | 14.99M | 12.46M |
| Gross Profit Ratio | 39.60% | 26.67% | 27.03% | 18.88% | 7.00% | 7.86% | 16.95% | -13.17% | -17.36% | 35.89% | 45.37% | 47.68% | 57.67% | 48.70% | 52.69% | 56.88% | 54.77% | 48.55% | 47.74% | 27.21% | 28.20% | 47.89% | 55.29% | 57.92% | 54.09% |
| Research & Development | 0.00 | 1.70M | 1.30M | 1.20M | 1.20M | 1.10M | 500.00K | 1.42M | 1.85M | 2.90M | 3.21M | 2.49M | 2.22M | 2.31M | 3.18M | 2.47M | 3.03M | 2.36M | 2.20M | 6.69M | 9.31M | 12.20M | 9.37M | 7.65M | 6.30M |
| General & Administrative | 10.32M | 13.51M | 10.61M | 9.00M | 8.32M | 9.45M | 6.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 8.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.42M | 13.61M | 10.71M | 9.10M | 8.42M | 9.45M | 6.49M | 6.19M | 7.06M | 24.15M | 25.04M | 22.02M | 19.15M | 10.93M | 10.32M | 10.80M | 11.47M | 12.14M | 12.22M | 17.50M | 17.32M | 24.20M | 21.64M | 14.91M | 11.53M |
| Other Expenses | 3.22M | 15.31M | 12.01M | 10.30M | 9.62M | -1.33M | 877.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 10.50M | 4.77M | 0.00 | 0.00 | 1.91M | 1.51M |
| Operating Expenses | 13.64M | 15.31M | 12.01M | 10.30M | 9.62M | 9.45M | 6.49M | 7.61M | 8.91M | 27.04M | 28.26M | 24.51M | 21.37M | 13.24M | 13.50M | 13.26M | 14.50M | 14.50M | 14.84M | 34.68M | 31.40M | 36.40M | 31.01M | 24.47M | 19.34M |
| Cost & Expenses | 22.82M | 22.21M | 18.46M | 15.24M | 12.53M | 12.09M | 7.92M | 9.38M | 10.85M | 44.41M | 43.30M | 40.98M | 34.90M | 23.52M | 23.92M | 23.61M | 24.98M | 26.55M | 28.34M | 59.28M | 55.72M | 55.97M | 48.21M | 35.36M | 29.92M |
| Interest Income | 0.00 | 12.00K | 20.00K | 470.00K | 2.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 74.00K | 270.00K | 216.00K | 0.00 | 0.00 | 160.00K | 626.00K | 2.45M | 2.01M | 0.00 |
| Interest Expense | 18.00K | 12.00K | 20.00K | 470.00K | 473.00K | 0.00 | 2.32M | 0.00 | 0.00 | 665.00K | 642.00K | 888.00K | 958.00K | 4.00K | 15.00K | 74.00K | 0.00 | 11.00K | 1.98M | 2.38M | 315.00K | 62.00K | 58.00K | 1.78M | 0.00 |
| Depreciation & Amortization | 1.52M | 1.52M | 1.44M | 1.36M | 1.35M | 1.27M | 743.00K | 112.00K | 489.00K | 2.25M | 2.75M | 2.28M | 2.10M | 708.00K | 855.00K | 882.00K | 950.00K | 1.95M | 4.28M | 4.01M | 8.75M | 3.99M | 3.68M | 1.91M | 1.51M |
| EBITDA | -4.32M | -10.65M | -7.05M | -8.77M | -8.22M | -7.96M | -5.45M | -1.60M | -8.65M | -10.51M | -12.65M | -5.02M | -830.00K | -2.27M | -1.04M | 600.00K | -981.00K | -973.00K | 1.77M | -6.76M | -7.44M | -18.28M | -6.06M | -7.57M | -5.37M |
| EBITDA Ratio | -28.41% | -119.82% | -92.32% | -109.24% | -205.50% | -111.66% | 353.86% | -523.12% | -513.43% | -80.83% | -58.52% | -22.95% | 15.70% | -16.26% | -8.62% | 8.39% | -1.99% | -5.02% | 10.32% | -12.99% | -21.96% | -29.33% | -15.67% | -32.22% | -23.31% |
| Operating Income | -7.62M | -12.80M | -9.61M | -9.15M | -9.40M | -13.91M | -15.51M | -7.82M | -9.20M | -17.32M | -15.76M | -9.50M | -2.97M | -3.61M | -1.90M | -368.00K | -3.32M | -3.13M | -2.51M | -29.06M | -22.59M | -21.70M | -9.74M | -9.48M | -6.88M |
| Operating Income Ratio | -50.14% | -135.96% | -108.63% | -150.13% | -300.74% | -485.75% | -900.23% | -502.18% | -556.26% | -63.96% | -57.21% | -30.19% | -9.30% | -18.02% | -8.61% | -1.53% | -14.33% | -13.37% | -9.72% | -86.00% | -66.70% | -57.78% | -25.32% | -36.61% | -29.88% |
| Total Other Income/Expenses | 1.77M | 619.00K | 1.10M | -1.45M | -2.32M | -2.06M | -5.18M | -515.00K | -1.22M | 3.90M | -282.00K | 1.32M | -6.77M | 628.00K | 18.00K | 86.00K | 243.00K | 198.00K | -2.45M | -5.26M | -5.82M | -2.98M | 2.36M | 996.00K | -1.20M |
| Income Before Tax | -5.85M | -12.18M | -8.52M | -10.60M | -13.31M | -15.97M | -20.69M | -8.27M | -10.14M | -13.42M | -16.04M | -8.18M | -9.74M | -2.98M | -1.88M | -282.00K | -1.93M | -2.93M | -4.96M | -34.47M | -22.89M | -21.26M | -7.38M | -8.48M | -8.08M |
| Income Before Tax Ratio | -38.51% | -129.39% | -96.25% | -173.97% | -425.74% | -557.72% | -1,201.04% | -531.09% | -613.31% | -49.54% | -58.24% | -25.99% | -30.46% | -14.88% | -8.53% | -1.18% | -8.33% | -12.53% | -19.20% | -102.00% | -67.60% | -56.61% | -19.18% | -32.77% | -35.08% |
| Income Tax Expense | 0.00 | 25.00K | 33.00K | 1.63M | -70.00K | -279.00K | 13.87M | -203.00K | 23.76M | 524.00K | -54.00K | 146.00K | 45.00K | 150.00K | 42.00K | 213.00K | 243.00K | 30.00K | 26.00K | -94.00K | 65.00K | 105.00K | 24.00K | 180.00K | 1.75M |
| Net Income | -5.85M | -12.20M | -8.55M | -12.23M | -13.24M | -15.69M | -20.69M | -7.62M | -32.95M | -13.94M | -15.99M | -8.33M | -9.78M | -3.13M | -1.92M | -495.00K | -2.11M | -3.43M | -14.99M | -34.37M | -22.96M | -21.37M | -7.40M | -8.66M | -9.83M |
| Net Income Ratio | -38.51% | -129.65% | -96.62% | -200.76% | -423.50% | -547.97% | -1,201.04% | -489.15% | -1,993.59% | -51.48% | -58.04% | -26.45% | -30.60% | -15.63% | -8.72% | -2.06% | -9.09% | -14.65% | -58.05% | -101.73% | -67.79% | -56.89% | -19.24% | -33.46% | -42.66% |
| EPS | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.81 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| EPS Diluted | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.80 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| Weighted Avg Shares Out | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
| Weighted Avg Shares Out (Dil) | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform
Nirmidas' test is available to POC healthcare providers with an Amazon business account Nirmidas' test is available to POC healthcare providers with an Amazon business account
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio's HemeScreen POL Offering by Q4-2021
Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2020 Results - Earnings Call Transcript
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2020 Results - Earnings Call Transcript
PRPO Increased Over 5% Pre-Market: Why It Happened
The stock price of Precipio, Inc. (NASDAQ: PRPO) increased by over 5% pre-market. This is why it happened.
Precipio Announces Q4-2020 and year-end Shareholder Update Call
Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST
Mr. Ron Andrews joins Precipio's Board of Directors
Company Strengthens Depth of Expertise in Products Industry Company Strengthens Depth of Expertise in Products Industry
Mr. Richard Sandberg is appointed Chairman of Precipio's Board of Directors
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman...
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
Partnership with ION Solutions expected to accelerate sales Partnership with ION Solutions expected to accelerate sales
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
Thousands of Oncology Practices will gain access to HemeScreen POL program Thousands of Oncology Practices will gain access to HemeScreen POL program
Source: https://incomestatements.info
Category: Stock Reports